The program which runs from July 1, 2026 through December 31, 2027 is designed to improve access to obesity treatment while expanding the use of medications that have been shown to help patients lose weight and reduce the risk of obesity-related health conditions
A separate trial with an active comparator group was deemed to be necessary for patients with HCV genotype 3 in light of the special clinical challenges presented in this population
- Possible side effects may include hypoglycemia, swelling, pain at the injection site, and increased growth of tumors if present
A flip-flop or dropped beat, often with a brief catching your breath feeling
RRM2 is a tumor-promoting gene that correlates with aggressive clinicopathologic features and functionally drives thyroid tumor growth in vitro and in vivo
Natural antioxidants show promising potential in reducing oxidative conditions and consequently maintaining the physiology of melanocytes